Recent Posts on This Topic | See All >
FHCRC initiates studies on ImmuneRegen BioSciences' cancer therapy candidateTags: cancer
[Source: CNN Money] - ImmuneRegen BioSciences Inc.®, a wholly owned subsidiary of IR Biosciences Holdings Inc. (OTCBB: IRBS), today announced the execution of an agreement with Fred Hutchinson Cancer Research Center to commence studies utilizing ImmuneRegen's Homspera. Under the agreement the Hutchinson Center will perform exploratory studies on Homspera, specifically focusing on the area of cancer immunotherapy. The Center expects to raise approximately $30 million within the next 3-4 years to support immunotherapy research projects and has recently announced a gift of approximately one-third of that amount. Studies at the Hutchinson Center will be performed under the direction of Dr. Cassian Yee , who has successfully used immune cells from patients with melanoma to cause long-term remission in their tumors.
Now available: “Action and Impact," a 2014 report on the grant programs and activities of the Flinn Foundation in Arizona biosciences, civic leadership, arts and culture, and the Flinn Scholars program.